India’s Sun Pharma Estimates Taro Buyout At $21.3 Million
This article was originally published in PharmAsia News
Executive Summary
Sun Pharmaceutical Industries of India now estimates its offer to buy all of Israel's Taro Pharmaceuticals will cost it about $21.3 million. The Indian drug maker has been trying to buy the Israeli firm ever since the companies had a falling out over a merger agreement just over two years ago. Each sued the other and Sun, which already owned 36 percent of Taro, has extended its open offer 10 times. Sun now is awaiting a decision by Israel's Supreme Court over the matter. Sun Chairman Dilip Shanghvi estimated the latest cost of the takeover. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.